ACOSOG Z0011 Trial

👉Data from the ACOSOG Z0011 trial suggests completion axillary dissection can be avoided for small cancers with clinically node-negative, sentinel node (SN)-positive disease, provided that systemic therapy and whole-breast irradiation (WBI) are incorporated into the treatment strategy for early-stage breast cancer following breast-conserving surgery (BCS).

👉This trial took clinically node-negative patients with 1 to 2 positive SNs by hematoxylin and eosin staining who were treated with BCS and whole-breast irradiation and assigned them into 1 of 2 arms:

👉One that received completion ALND versus the other that received only SLNB.

👉The 10-year overall survival in the SLNB only group versus the completion ALND group was 86.3% and 83.6%, respectively.

👉Similarly, disease-free survival was 80.2% and 78.2%, respectively.

👉The study demonstrated that the 10-year in-breast recurrence rate was higher in the ALND group, 5.6% versus 3.8% (P=0.13) than in the sentinel lymph node resection only group.

👉Regional recurrence occurred in less than 1.5% of patients in both arms.


  1. Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252:426-432.

#Arrangoiz #BreastSurgeon #BreastCancer #CancerSurgeon

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s